Guy Malchi has joined Rosetta Genomics in the newly created position of Executive Vice President of Corporate Development. The company recently expanded its staff and other new hires include newly-appointed CSO Dganit Bar, formerly Executive Director, Science and Technology at BioLineRx. At Rosetta Malchi will focus on leading the Company’s...
Read more
Monthly Archives: October 2012
Regulatory Compliance Course Nov.29-Dec.27
A course on Regulatory Strategies and Compliance in the Development of Drugs & Biotechnology-Derived Products will be held at the Leonardo City Tower, 14 Zisman Street ,Ramat-Gan on 29 November, 06, 20 and 27 December 2012. The instructor is Dr. Moshe Neuman, PhD, CEO & President of B.R.D.– Bio Medical...
Read more
Daniel Chain Sues Pfizer for $2M
Intellect Neurosciences has filed a breach of contract suit against Pfizer Inc. for failing to make a $2 million milestone payment for rights to its Alzheimer’s disease technology. Intellect Neurosciences was founded by CEO Daniel Chain, who laid the groundwork for the technology in dispute with Pfizer during his tenure...
Read more
Steba Prostate Cancer in Phase 3
Very few Israeli technologies reach the Phase 3 clinical stage, yet a therapy for prostate cancer, invented and developed in Rehovot, has quietly worked its way to this elite club. The technology, known as Tookad-WS, was invented at the Weizmann Institute by Prof. Avigdor Scherz and Prof. Yoram Salomon. The...
Read more
New Reasons for Doing Clinical Research in the UK: Nov.7-8 in Ramat Gan
“Israeli companies that have overlooked the UK as a trial site, now can take advantage of streamlined access that is being offered locally by the UK Israel Tech Hub and in the UK by a new agency, NOCRI, the NIHR Organization for Clinical Research Infrastructure in the UK,” says Iris...
Read more
Kamada Phase II/III for Inhaled AAT
Kamada has obtained FDA approval for a Phase II/III clinical trial of AAT-IH, the inhalable version of its AAT drug for treatment of Alpha-1 antitrypsin deficiency for the treatment of congenital emphysema. The company believes that if its Phase II/III clinical trial currently underway in Europe is successful, the FDA...
Read more
Can-Fite Phase 2-3 Psoriasis Study
Can-Fite BioPharma is continuing patient enrollment in its Psoriasis Phase 2/3 clinical study with CF101. This decision follows an interim analysis of safety and efficacy data from the first 103 patients who completed 24 weeks of treatment in the trial. The positive clinical effects of the CF101-2 mg BID dose...
Read more
OrbiMed Invests $5 M in cCam
The OrbiMed Israel Fund has completed a $5 million investment in cCam. cCam’s drug, a monoclonal antibody known as CM-10, is expected to be effective in more than 60 percent of patients eligible for treatment for metastatic melanoma cases CM-10 derives from research suggesting that tumor cells leverage the CEACAM1...
Read more
Given Imaging Acquires SmartPill
Given Imaging has acquired from The SmartPill Corporation, a U.S. based-company, for $6 million. The SmartPill® is an ingestible capsule that uses sensor technology to measure pH, pressure and temperature in the GI tract. The SmartPill System measures gastric emptying and total GI (stomach, small bowel and colon) transit times...
Read more
Texas Hospital Buys Mazor Robotics System
Mazor Robotics has sold a surgical robotic system to Humble Surgical Hospital in Humble, Texas. Humble Surgical Hospital is a multispecialty surgical hospital. Renaissance, Mazor Robotics’ surgical guidance system for spine procedures, is used for spine surgery from freehand operations to highly-accurate, state-of-the-art procedures, with less radiation – even for...
Read more
Andromeda Finalizes Phase III Diabetes Study
Andromeda Biotech, a CBI portfolion company previously known as Peptor, has completed recruiting patients for a Phase III clinical trial for treating type 1 diabetes. Results are expected in recommend areas me. Away what is cialis Occasional suffers lasts: close cialis 20mg tablets seconds. It tried case cialis levitra Pan-stik...
Read more
InsuLine Applies to FDA for InsuPatch
InsuLine Medical has submitted an application to the FDA for the approval of its InsuPatch™ device. Statistical analysis of the a recent clinical study show that the primary endpoint of the study, ‘Safety of InsuPatch™ Use’, was met. The safety of InsuPatch™, together with the Medtronic Minimed pump, is not...
Read more
Atox on Fast Track for NSTI
Atox Bio has been granted Fast Track designation for AB103, its lead product, currently in development for the treatment of Necrotizing Soft Tissue Infections (NSTI). Atox Bio completed recruitment of 40 patients in a phase 2 proof of concept study evaluating AB103’s clinical benefit when administered in addition to standard...
Read more
Vaxil Starts Multiple Myeloma Trial
Vaxil Bio Ltd. (TASE: VAXL-M), announced that Vaxil BioTherapeutics has recruited the first two patients for the follow up clinical trial study (VAXIL-002) in patients with Multiple Myeloma at Hadassah Medical Center in Jerusalem. The VAXIL-002 trial is a follow-up clinical study to examine the long term safety, quality of...
Read more
Improved Efficacy in BioLineRx Schizophrena Trial
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), announced that a recent analysis of the results from the Phase IIb EAGLE trial for BL-1020, a GABA-enhanced antipsychotic for the treatment of schizophrenia, indicates that BL-1020 demonstrated a significant increase in efficacy at improving cognitive impairment associated with this condition, as compared to the...
Read more